MADRID (dpa-AFX) - Grifols S.A. (GRFS) on Tuesday reported higher profit for the first half of 2026, supported by growth in its Biopharma business. The company also reaffirmed its full-year guidance.
For the six months, group profit increased 28.7% to €227 million from €177 million a year earlier. Revenue rose 2.6% at constant currency to €3.57 billion, driven by 5.4% growth in the Biopharma segment, led by a 12.8% increase in its immunoglobulin franchise.
Adjusted EBITDA increased 2.4% at constant currency to €854 million, with the adjusted EBITDA margin improving to 23.9% from 23.8% a year ago.
During the period, Grifols completed the refinancing of all 2027 debt maturities and redeemed €500 million of its 2030 bond, extending its debt maturity profile with no significant maturities until the fourth quarter of 2028.
Looking ahead, Grifols reaffirmed its full-year 2026 guidance, citing continued strength in immunoglobulins, progress in its Egypt plasma expansion, the Biotest turnaround, disciplined cost management and improving free cash flow generation.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
